COVER STORY
By: BY DOMINIK MORHARD, M.D., MAXIMILIAN F. REISER, M.D., AND BIRGIT ERTL-WAGNER, M.D.
DEPARTMENTS
Agenda
By: DONNA DOMINO
Overread
Newsclips
Diagnostic Imaging supplement
Your Outpatient Practice
X-Ray Vision
Cancer Care
Digital Practices
Tech Watch
Backscatter
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.